Research programme: cancer immunotherapies - Genocea Biosciences

Drug Profile

Research programme: cancer immunotherapies - Genocea Biosciences

Alternative Names: GEN-009; Neoantigen cancer vaccine - Genocea Biosciences

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Genocea Biosciences; Memorial Sloan-Kettering Cancer Center
  • Developer Dana-Farber Cancer Institute; Genocea Biosciences; Harvard Medical School; Memorial Sloan-Kettering Cancer Center; US Oncology Research
  • Class Immunotherapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma

Most Recent Events

  • 16 Feb 2017 Genocea plans to file an IND application with the US FDA in the fourth quarter of 2017
  • 18 Jan 2017 Genocea Biosciences enters into an agreement with US Oncology Research to build preclinical data which will support clinical trials of a personalised cancer vaccine (Genocea Biosciences website) before January 2017
  • 18 Jan 2017 Preclinical trials in Malignant melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top